Funder: NIH National Institute of Mental Health (NIMH)

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.

Topics: Prevention, PPE, Social Distancing, Mobile Health, Wearables, Telemedicine, App, Mental Health, Immunology, Host Response, Host Factors, Research Site, Community-based, Research Model Development, Research Methods, Prognostics, Immunity, Co-Morbidities, Diabetes, COVID-19, Neurological Disorders, Substance Abuse, Clinical Trial, Clinical Presentation of Infection, Pneumonia, Long-term Impact of Infection, Inflammation, Cellular / Molecular Response, ARDS, Healthcare Implementation, ELSI (Ethical, Legal, and Social Implications), Health Disparities, Epidemiology, Transmission, Aerosol, Surveillance, Risk Factors, Incidence, Contact Tracing, Clinical Outcome, Clinical History, Environmental Health, Community Engagement, Diagnostics, Viral Detection, Diagnostics Development, Diagnostic Efficacy, Diagnostic Scalability, Diagnostic Reliability, Antibody Detection, Social Determinants of Health, Target Population, Children, Elderly, Homeless Persons, Non-Human Animals, Pregnant Women, Teens, Treatments, Antibody-based Treatment, Convalescent Serum, Drug Development, Drug Repurposing, Anti-viral Targets, Immunological Response Targets, Drugs, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Vaccines, Vaccine Hesitancy